Track market-moving stories before they get noisy

Image credit: Powerus.

On Thursday, Powerus became a public company on Nasdaq.

By Friday, its shares were on Solana.

The sequence captures two technological shifts that initially seem unrelated.

Powerus is building autonomous drones and counter-drone systems intended to move humans farther from the physical point of danger. At the same time, tokenized equities are beginning to move investors beyond the traditional brokerage infrastructure through which public stocks have historically been held and traded.

In both cases, more of the execution layer is moving into software.

Powerus completed its merger with Nasdaq-listed Aureus Greenway Holdings on October 1. Legacy Powerus shareholders emerged with roughly 83% of the common stock and approximately 93% of the combined company’s voting power, effectively transforming the listed entity into Powerus Corporation. (Thaler)

One day later, Backpack Securities issued a tokenized representation of PUSA on Solana through Sunrise. Each token is designed to be redeemable 1:1 for an underlying Powerus share and transferable back into traditional brokerage infrastructure for eligible investors. (Solana Compass). As of 2:45pm on the day of release $PUSA has reached $9.1m in trading volume.

Powerus announced on X: “We’re now live on Solana. $PUSA is our common stock onchain, redeemable one to one for the Nasdaq-listed share.”

We’re now live on Solana.

$PUSA is our common stock onchain, redeemable one to one for the Nasdaq-listed share, trading nights, weekends and holidays.

Powerus (@powerus_usa), October 2, 2026

Powerus did not issue a cryptocurrency, and PUSA on Solana is not a corporate memecoin.

The underlying asset remains a Nasdaq-listed security.

What changed is the rail on which it can travel.

The battle-tested brain behind the machine That distinction between the physical asset and the intelligence controlling it also sits at the center of Powerus’ business.

The company isn’t positioning itself merely as another drone manufacturer. It is building autonomous aircraft, counter-drone interceptors and the command software connecting them.

Drone airframes are becoming increasingly commoditized. Motors, batteries, cameras and other components can come from a growing collection of suppliers.

The potentially more defensible layer is the intelligence deciding what those machines see, how they coordinate and what they do next.

Powerus’ xNav AI architecture is designed to combine data from radar, visual sensors and other sources into a common operating picture, identify threats and coordinate autonomous systems.

In that sense, Powerus has built the battle-tested brain behind the machine: so the person behind it never has to be in the line of fire.

The background of co-founder and president Brett Velicovich helps explain why that philosophy runs through the company.

Velicovich served as a U.S. Army Special Operations intelligence analyst from 2001 to 2010, completing six combat tours in Iraq, Afghanistan and Somalia. According to Powerus’ SEC-filed biography, he worked within America’s covert drone program tracking high-value terrorist targets. He later wrote Drone Warrior, an account of his experience with military drone operations, and earned an MBA from Duke University’s Fuqua School of Business. (SEC)

Advertisement

His relationship with drones didn’t end with the military. Velicovich subsequently applied the technology to wildlife conservation in Kenya and other humanitarian work. He was also in Ukraine within days of Russia’s full-scale invasion, where he saw firsthand how inexpensive drones and rapid battlefield iteration were changing modern warfare. He has said Powerus’ founders ultimately came together through their experience in Ukraine. (LinkedIn)

That gives Powerus an unusual founding perspective: not simply engineers asking what autonomous systems can do, but operators thinking about what someone in the field actually needs them to do.

The company’s Guardian counter-drone system, for example, is designed to intercept hostile UAVs before they reach personnel or critical infrastructure. Powerus reports an approximately 89% interception success rate per launch in manual and semi-autonomous operations, although that remains a company-reported figure rather than an independently verified government statistic.

Its subsidiary Tandem Defense has also secured a U.S. Air Force IDIQ contract for Guardian-2 with a ceiling of up to $90 million through mid-2028. The ceiling is not guaranteed revenue, but it gives Powerus a vehicle through which the government can place future orders.

Going public is intended to give the company more capacity to pursue that scale.

“Completing this transaction puts Powerus in a position to build at the scale our customers are asking for,” CEO Andrew Fox said following the merger. (Nasdaq)

For Powerus, that means more manufacturing, more autonomous systems and potentially more acquisitions.

For investors, however, what happened immediately afterward may prove just as interesting.

From a Florida golf company to Nasdaq: and Solana Powerus took an unconventional route to the public markets.

Aureus Greenway Holdings originally operated two Florida golf courses and completed its own Nasdaq IPO in February 2025. By late 2025, the small public company was evaluating strategic alternatives.

It ultimately became Powerus’ route onto Nasdaq.

The merger was announced in March, Aureus adopted the PUSA ticker ahead of closing, and on October 1 the transaction was completed and Aureus renamed itself Powerus Corporation. (Nasdaq)

The transaction also brought prominent financial backers. The merger announcement identified Eric Trump and Donald Trump Jr. as notable investors in the combined company through American Venture Partners, alongside other investors including drone manufacturer Unusual Machines and a $50 million strategic investment. (SEC)

But what happened on October 2 represents a different kind of capital-markets experiment.

Backpack Securities took the newly combined PUSA equity and put a tokenized version on Solana roughly a day after the merger closed.

That speed is notable.

A company can complete a major corporate transaction inside the conventional securities system on Thursday and have an onchain representation of its equity circulating through blockchain infrastructure on Friday.

The gap between going public and going onchain is beginning to disappear.

Tokenization’s democratization story Crypto has talked about democratizing finance for years.

Tokenized equities offer a more concrete version of that argument.

They do not necessarily create new assets. They change how existing ones can be distributed.

A traditional stock generally lives inside brokerage infrastructure. Moving it from one institution to another is possible, but ownership remains tied to a complex network of brokers, custodians, clearing systems and market hours.

Putting a compliant representation of that security on a blockchain begins to make the asset behave more like software.

It can exist in a wallet.

It can settle against stablecoins.

It can move through blockchain applications.

And, eventually, tokenized securities could interact with lending protocols, collateral systems and other programmable financial infrastructure.

There are still substantial limitations. Backpack Securities’ tokenized-equity service is restricted in jurisdictions including the United States, and securities law does not disappear simply because an asset moves onto a blockchain. (Solana Compass)

So tokenization has not suddenly made every U.S. equity permissionless or universally accessible.

The more important change is portability.

Nasdaq can remain where a company establishes its public equity, while networks such as Solana become additional rails on which that equity can move.

That makes PUSA interesting beyond Powerus itself.

The significance isn’t that a drone company now has a token.

It is that a conventional public company’s shares could acquire a blockchain-native distribution layer almost immediately after a transformational corporate transaction.

And that brings the two sides of the Powerus story together.

On the battlefield, Powerus is trying to transfer more sensing, coordination and execution from humans to software so operators can remain farther from danger.

In capital markets, blockchains are transferring more ownership, settlement and distribution functionality into software so financial assets can move beyond the systems in which they were originally issued.

Neither eliminates humans or institutions.

Both make the underlying infrastructure more programmable.

Powerus is building the brain behind the machine.

Blockchain is becoming another rail beneath the asset.

PUSA managed to connect those two narratives in roughly 24 hours.

The author holds a position in $pusa

Disclosure: This article was edited by Han Kao. For more information on how we create and review content, see our Editorial Policy.

Solana’s native cryptocurrency SOL is trading near $120, as fresh data shows record-breaking adoption of tokenized equities on the Solana blockchain. The network’s user base for tokenized-equity assets recently crossed 1.2 million individual holders, indicating a surge in both activity and on-chain participation.

Tokenized equity growth drives network adoptionSolana, a high-performance blockchain designed for decentralized applications, reported that 775,000 new tokenized-equity holders joined the network in September alone. This brought the total number of unique holders to an all-time high of 1.2 million at the end of the month.

Tokenized equities on Solana hit an all-time high of 1.2 million holders, with 775,000 joining in September alone.

The pace of adoption notably accelerated during the last weeks of September, following a period of gradual growth earlier in the year. This uptick reflects increasing interest in tokenized versions of traditional assets, providing users with a new way to engage with the Solana network beyond speculative trading.

Mini dictionary: Tokenized equity, a digital representation of traditional equity shares on a blockchain, allows users to trade, transfer, or hold fractional ownership in assets using blockchain technology. This increases accessibility and potentially streamlines settlement processes.

Broader interest in tokenized financial assets adds an important dimensional layer to SOL’s continued presence near its recent peak price levels.

SOL maintains strength above key technical levelsAs of the latest data, SOL trades at $119.93, up 1.28% in the past 24 hours and hovering close to its recent high of $123.76. On the daily chart, SOL remains well above significant support levels, including its 50-day moving average of $85.72 and its 200-day moving average at $102.94.

Date/LevelSOL Price50-day MA200-day MARecent HighKey SupportCurrent$119.93$85.72$102.94$123.76$94.85The 200-day moving average in particular provides a critical technical reference for traders monitoring downside risk, while the $94.85 zone has also emerged as a crucial support area.

Resistance is visible at the recent daily high of $123.76. A solid move above this could signal a fresh phase in Solana’s rally. Should the breakout not materialize, attention could return to established support levels around $102.94 and $94.85.

Momentum indicators remain supportive. The relative strength index (RSI) stands at 63.82, with its short-term average near 65.48, staying below the traditional 70 level associated with overbought conditions. This suggests ongoing buying interest without extreme overheating.

Market activity and investor focusOpen interest in Solana derivatives remains high at around $6.5 billion, according to CoinGlass, sustaining elevated levels through recent months. Trading volume has also been robust, frequently exceeding $9 billion on several trading days during the period reviewed.

The combination of strong market liquidity, ongoing derivatives activity, and increased adoption of tokenized equities has added new context to SOL’s recent price structure.

SOL maintains its momentum above key moving averages, as fresh adoption data brings a meaningful new catalyst to the network.

Key levels and outlook for SOL priceTraders are closely monitoring the $123.76 resistance level and $120 psychological zone as immediate reference points. A firm break above recent highs could reinforce the network’s bullish technical outlook.

To the downside, the 200-day moving average at $102.94 and the $94.85 level are viewed as important support areas. Technical analysts suggest these figures may provide guidance for near-term volatility and potential market pullbacks.

With the rise in tokenized-equity participation and SOL’s technical position above crucial indicators, the coming days are expected to test whether buyers can sustain upward momentum or if sellers will drive a correction toward lower support zones.

Archer Aviation (ACHR.N) said on Friday a California federal court had dismissed some of Joby Aero's ​trade-secret and contract claims against it, as well ‌as Archer's counterclaims.

The US District Court for the Northern District of California issued the ruling on September 29, cutting back ​on the claims in the ongoing litigation between ​the two air-taxi makers.

Air taxi makers are racing ⁠to commercialize electric vertical takeoff and landing aircraft — an ​emerging market backed by major automakers, airlines and investors ​that has also spawned a string of trade-secret and patent disputes.

Archer settled separate trade-secret claims brought by Boeing-owned air-taxi developer Wisk in ​2023, and filed a patent infringement lawsuit against ​Vertical Aerospace earlier this year.

Joby sued Archer in 2025, alleging a former ‌employee, ⁠George Kivork, who led its state and local policy team, took confidential information on business strategies, partnership terms and aircraft specifications before joining the rival.

A forensic investigation found ​Kivork had ​sent dozens of ⁠Joby files to a personal email account and altered security permissions on hundreds ​more to access them after his departure, the ​lawsuit ⁠said.

Joby also alleged Archer misused the trade secrets to undercut one of its agreements with a real-estate developer.

The company ⁠sought ​an unspecified amount of monetary ​damages and an order preventing Archer from using its trade secrets.

Booz Allen Hamilton (BAH - Free Report) ended the recent trading session at $67.35, demonstrating a -4.43% change from the preceding day's closing price. This change lagged the S&P 500's 0.73% gain on the day. Meanwhile, the Dow experienced a rise of 0.49%, and the technology-dominated Nasdaq saw an increase of 1.19%.

Shares of the defense contractor witnessed a loss of 4.62% over the previous month, beating the performance of the Business Services sector with its loss of 4.68%, and underperforming the S&P 500's gain of 0.55%.

The investment community will be closely monitoring the performance of Booz Allen Hamilton in its forthcoming earnings report. The company is scheduled to release its earnings on October 23, 2026. In that report, analysts expect Booz Allen Hamilton to post earnings of $1.44 per share. This would mark a year-over-year decline of 3.36%. Meanwhile, the latest consensus estimate predicts the revenue to be $2.8 billion, indicating a 3.09% decrease compared to the same quarter of the previous year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $6.25 per share and a revenue of $11.45 billion, signifying shifts of -3.99% and +2.08%, respectively, from the last year.

Investors should also note any recent changes to analyst estimates for Booz Allen Hamilton. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.15% higher within the past month. As of now, Booz Allen Hamilton holds a Zacks Rank of #3 (Hold).

Looking at its valuation, Booz Allen Hamilton is holding a Forward P/E ratio of 11.28. This signifies a discount in comparison to the average Forward P/E of 15.27 for its industry.

We can additionally observe that BAH currently boasts a PEG ratio of 1.72. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Consulting Services industry stood at 1.13 at the close of the market yesterday.

The Consulting Services industry is part of the Business Services sector. At present, this industry carries a Zacks Industry Rank of 77, placing it within the top 32% of over 250 industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.

By You're currently following this author! Click to unsubscribe from email alerts.

Apple plans new user controls for apps seeking Full Disk Access on Macs, citing increasingly capable AI agents. Kevin Carter/Getty Images Apple wants to make sure you know exactly what you're signing up for before giving an AI agent access to your Mac.

The company said in a developer blog post on Friday that it plans to introduce additional privacy controls for macOS's "Full Disk Access" setting, which gives apps permission to read sensitive information, including emails, private messages, browsing history, and other personal files.

"Some developers are using Full Disk Access in ways that could put users at risk, exposing everything on their systems — including files, mail, messages, and even browsing history — without users' full knowledge and understanding," Apple said.

"Going forward, we will introduce additional controls to ensure that users who genuinely wish to grant an app this extraordinary level of access can only do so with very explicit user action," Apple added. "As AI agents become increasingly capable and autonomous, the risks associated with this level of access will grow substantially."

For Mac users, that means granting apps a sweeping level of access will require 'very explicit user action,' without explaining how that will differ from the current process. Apple hasn't detailed exactly how the new safeguards will work or when they'll arrive. The company did not say the changes would apply only to AI agents; it said the risks of permission will grow as agents become more capable and autonomous.

According to the blog post, the setting was originally intended to help backup software operate, but increasingly capable AI agents are creating new risks.

Last month, Inc. columnist Jason Aten alleged that Meta's Muse AI agent had accessed private messages on his Mac mini without his permission. Meta disputed the claim.

Andy Stone, Meta's vice president of communication, wrote in a post on X that "the Messages integration in the Muse app for Mac is entirely opt-in."

"You have to enable both Full Disk Access and the Messages connector for Muse to be able to read your Messages content," Stone said. "It can't read your Messages unless you do this. And it can be revoked at any time."

Read next

Katherine Li You're currently following this author! Click to unsubscribe from email alerts.

Katherine Li is a reporter on Business Insider's West Coast business news team. She covers career,  the future of work, and how AI is changing hiring practices and workplace trends.Previously, she was a newsroom fellow who wrote international breaking news and produced newsletters for Semafor. Before that, she wrote about climate policies for The Lever, covered the AAPI community for the SF Chronicle as a freelancer, and wrote about the 2019 Hong Kong protests as an intern for The New York Times.She is an alumna of the Graduate School of Journalism at UC Berkeley and a graduate of the international journalism program at Hong Kong Baptist University with minors in French and English literature.  Email Katherine at [email protected] and follow her on Bluesky @katherineli.bsky.social. 

Apple AI Big Tech More Innovation Tech

Mastercard, the global payments network MA , launched Advanced B2B Analytics to help banks find suppliers willing to take card payments, with shares up about 0.3% to $551.65 on Oct. 2. The pitch is straightforward: turn payment data into more commercial-card spending. The valuation graphic puts the stock 19.69% below its $686.88 GF Value estimate, suggesting potential upside if that estimate holds.

The tool scans accounts-payable data, scores suppliers' likelihood of accepting cards and gives banks a clearer target list. Mastercard named Absa Group and Emirates NBD among the first banks offering it to corporate customers. Dashboards and working-capital insights round out the package. The release provides no customer total, pricing details or payment volume generated, leaving the commercial payoff unquantified.

For investors, the appeal is the link between advice and transactions. If banks use those scores to persuade suppliers to accept cards, Mastercard could capture more payment activity. But a promising supplier list is only the starting point. Banks must act, suppliers must agree and spending must follow. The number to watch is incremental card volume—not how many recommendations the software produces.

Item 1 of 2 The Ice Age's Scrat and his Acorn balloon are carried during the 91st Macy's Thanksgiving Day Parade in New York, New York, U.S., November 23, 2017. REUTERS/Carlo Allegri

[1/2]The Ice Age's Scrat and his Acorn balloon are carried during the 91st Macy's Thanksgiving Day Parade in New York, New York, U.S., November 23, 2017. REUTERS/Carlo Allegri Purchase Licensing Rights, opens new tab

Oct 2 (Reuters) - Disney (DIS.N), opens new tab agreed to license a slate of movies and TV shows to Netflix (NFLX.O), opens new tab, ​including existing "Ice Age" films as well ‌as "Percy Jackson and the Olympians" and "Will Trent" series, the companies said on Friday.

Here are some more ​details:

Sign up here.

The deal expands Netflix's access to Disney-owned ​content as the streaming platform broadens ⁠its library through licensing agreements, including a ​deal with AMC Global Media (AMCX.O), opens new tab in July to ​bring "The Walking Dead" series to its platform.

The first two seasons of Disney+ original series "Percy Jackson and the ​Olympians" will be available globally on ​Netflix from October 4 for three months.

The five "Ice Age" ‌films ⁠will also begin streaming globally on Netflix for three months, ahead of the theatrical release of "Ice Age: Boiling Point" early next year.

The ​deal also ​includes a ⁠selection of Disney and Pixar films, including "Soul", "Elio" and "Raya and the Last ​Dragon", which will be available globally ​on ⁠Netflix from early 2027, with varying launch dates and regions.

Disney-branded titles largely remain exclusive ⁠to ​its streaming platforms and TV ​channels, as per the company.

Reporting by Akash Sriram and ​Angela Christy in Bengaluru; Editing by Vijay Kishore

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Intel, the processor manufacturer and contract-foundry contender
INTC -0.56% 70

, advanced its High-NA chipmaking program, while shares traded at $121.76, up nearly 1.5%, around 12:53 p.m. ET on October 2. Its September update with ASML showed the technology moving beyond qualification into production on selected layers of some Panther Lake processors. That gives Intel something concrete to show prospective foundry customers. Turning that progress into orders is the next hurdle.

ASML's September 8 announcement reported more than one million wafers processed across testing, research and production, with throughput, availability and overlay meeting Intel's expectations. That total is not one million commercial wafers. Intel's stitching technology also lets customers work with current six-inch masks while the industry develops larger formats. Together, those advances can ease adoption, but the announcement provides no figures for manufacturing costs or external customer volumes.

The valuation picture leaves little room for disappointment: shares sit 277.89% above the $32.22 GF Value estimate. Technical progress can strengthen Intel's sales pitch, but it does not establish foundry profitability. Investors still need evidence of competitive yields, disciplined spending and paying customers at scale. Intel has cleared a manufacturing hurdle. The stock price demands a business payoff.

Check the Warning Signs for

INTC

now!

One of the great challenges for a veteran business is staying relevant through the years. General Mills, anchored by a clutch of familiar food brands like Cheerios and Chex cereals and Häagen-Dazs ice cream, is a bit out of tune with current consumer tastes. That's affecting the company's results and, relatedly, investor sentiment.

In September, an earnings report showing declines in key fundamentals, and a CEO appointment that some took as a discouraging, don't-rock-the-boat move, exacerbated the situation. General Mills' stock price fell by almost 22% that month.

Image source: Getty Images.

Not very tastyGeneral Mills unveiled its first quarter of fiscal 2027 results on the morning of Sept. 23, and they fell into the good news/bad news category. The good was that the company notched a double beat on analyst estimates, with net sales of $4.4 billion and net income not under generally accepted accounting principles (non-GAAP, or adjusted) of $0.75 per share.

The bad news is that both core fundamentals were down year over year, not least because each of the company's three U.S. business units posted sales declines. On top of that, it reaffirmed its full-year 2027 guidance: net sales are likely to slip again, with management forecasting a 1.5% decline to a 0.5% increase over the 2026 result. As for the bottom-line estimate, adjusted earnings per share (EPS) are predicted to land at $3 to $3.20. That compares unfavorably with fiscal 2026's $3.55.

Several analysts adjusted their takes on General Mills after earnings. Apparently, the ones investors took to heart were those featuring price target cuts. This was the case with the prominent Bank of America (BAC +0.04%) Securities, whose analyst Peter Galbo reduced his fair value assessment to $40 per share from $43. He also maintained his lukewarm neutral rating on the stock. Bernstein SocGen's Alexia Howard shaved $1 off her price target to land at $30 per share while keeping her underperform (sell, in other words) recommendation intact.

Premium Feature

Moneyball Superscore

48/100

Today's Change

(

1.07

%) $

0.34

Current Price

$

32.01

New boss, same old worriesOn the last day of the month, General Mills announced it had selected a new CEO to succeed outgoing chief Jeff Harmening. The new boss will be Dana McNabb, a 27-year veteran of the company who currently serves as COO; she'll take up the position on Jan. 1 of next year.

In a well-performing company, investors often take such a promotion from within as a comforting sign that management doesn't want to mess with success. The perception is different in a struggling business, as few people are eager to see more of the same. We won't know if McNabb will be different and/or innovative as a leader until she starts leading, so those worries are understandable.

As is that month's sell-off. After all these years, with the healthy-eating trend in force, General Mills still seems reluctant to lean into it meaningfully. Its current strategy of focusing on its eight "core brands," such as Pillsbury, indicates a continuing resistance to change, in my view. As an investor, if I were looking at food industry stocks, I'd probably wouldn't pick this one as a buy.

Taiwan Semiconductor Manufacturing, the advanced-chip foundry
TSM +2.96% 97

, outlined plans to bring High-NA lithography into advanced-node volume production starting in 2030, while its U.S. shares traded around $473.41, up approximately 3.1%, around 12:34 p.m. ET on October 2. The technology roadmap stretches years ahead. The valuation already demands execution: the stock sits 27.49% above its $371.32 GF Value™, leaving less room for disappointment.

The rollout has two stages. TSMC plans to start with existing six-inch masks, while its joint initiative with ASML targets a 12-inch-mask pilot line in 2031 and production-ready lithography systems in 2033. Larger masks could let scanners process chips more efficiently and remove constraints from stitching separate exposures together. Those improvements could lower manufacturing costs as AI chips become increasingly complex.

That timetable gives TSMC a way to introduce High-NA before the larger-mask infrastructure is ready. But better technology still has to earn its keep. Investors need proof that manufacturing savings and stronger output can cover the cost of equipment and qualification. With shares carrying a hefty premium to GF Value™, successful deployment alone may not be enough. The economics need to deliver, too.

Check the Warning Signs for

TSM

now!

Dell Technologies, the enterprise-computing and AI-server company
DELL +3.84% 69

, raised its fiscal-2027 AI-server revenue forecast from $60 billion to $74 billion, with shares up approximately 4.4% to $565.50 around 12:14 p.m. ET Friday. That is a $14 billion upgrade. AI servers now account for roughly 38.5% of Dell's $192 billion annual revenue outlook. This business is carrying serious weight.

The bigger test sits inside the order book. Dell reported a $95 billion AI-server backlog at the end of July, after taking in $60.9 billion of orders and generating $16.4 billion in quarterly AI-server revenue. Demand looks enormous. Turning those commitments into delivered systems, profits and cash is the next hurdle. Component availability, deployment schedules and customer readiness all matter.

The valuation picture shows Dell trading 141.43% above its $234.23 GF Value estimate, leaving little room for execution slips. That estimate is a valuation reference, not a ceiling. Still, investors are paying for a hefty dose of future growth. Dell needs to ship the backlog while protecting margins and keeping working capital under control. Big orders make the growth story compelling. Profitable deliveries make it stick.

Check the Warning Signs for

DELL

now!

-

HONOLULU--(BUSINESS WIRE)--Bank of Hawai‘i Corporation (NYSE: BOH) (the “Company”) will release third quarter 2026 financial results on Monday, October 26, 2026 before the market opens and hold its quarterly conference call at 2:00 p.m. Eastern Time (8:00 a.m. Hawai‘i Time) on the same day.

The live call, including a slide presentation, will be accessible on the investor relations link of the Company's website, www.boh.com. The conference call link is
https://register-conf.media-server.com/register/BIca3756a1006c4dff84049e53b338c6cf.

A replay of the webcast will be available for one year beginning at approximately 11:00 a.m. Hawai‘i Time on Monday, October 26, 2026. The replay will be available on the Company's website, www.boh.com.

Additionally, the Board of Directors declared a quarterly dividend payment of $10.94 per share, equivalent to $0.2735 per depositary share, of Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series A, and a quarterly dividend payment of $20.00 per share, equivalent to $0.5000 per depositary share, of Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B. The depositary shares representing the Series A Preferred Stock and Series B Preferred Stock are traded on the NYSE under the symbol “BOH.PRA” and “BOH.PRB”, respectively. The dividends on the Series A Preferred Stock and Series B Preferred Stock will be payable on November 2, 2026 to shareholders of record of the preferred stock as of the close of business on October 16, 2026.

Bank of Hawai‘i Corporation is a regional financial services company serving businesses, consumers and governments in Hawai‘i and the West Pacific. The Company’s principal subsidiary, Bank of Hawai‘i was founded in 1897. For more information about Bank of Hawai‘i Corporation, see the Company’s website, www.boh.com. Bank of Hawai‘i Corporation is a trade name of Bank of Hawaii Corporation.

More News From Bank of Hawai‘i Corporation

Back to Newsroom

Micron Technology delivered impressive results for the fourth quarter of fiscal 2026 on Sept. 30, indicating that the artificial intelligence (AI) infrastructure boom is alive and well.

Micron makes memory and storage chips that play a critical role in AI data centers by transporting and storing the large volumes of data needed to train models and run inference applications. So, it wasn't surprising to see the company's results and guidance crushing expectations, paving the way for more upside in Micron stock this month.

However, there is another key AI chip company that's poised to hold an important event in October. Marvell Technology (MRVL +1.57%) has scheduled its Investor Day for Oct. 6. Let's see why this date could be significant for Marvell investors and trigger a rally in the company's shares.

Image source: The Motley Fool.

Marvell Technology is expected to raise guidance on Oct. 6Marvell Technology manufactures custom AI processors and networking chips. Both these markets have been growing at an incredible pace. Counterpoint Research estimates that shipments of custom AI processors will triple between 2024 and 2027. Meanwhile, Goldman Sachs notes that networking will be the next big bottleneck in the AI infrastructure market. The investment bank expects the optical networking market's revenue to jump over 10x between 2026 and 2028.

Premium Feature

Moneyball Superscore

87/100

Today's Change

(

1.57

%) $

4.21

Current Price

$

272.29

These catalysts explain why Marvell Technology has been consistently raising its guidance in recent quarters. The semiconductor specialist raised its fiscal 2027 revenue outlook to $12 billion, up from the prior estimate of $11.5 billion in August. It also increased its fiscal 2028 revenue guidance by $1.5 billion to $18 billion.

It is worth noting that Marvell called for $11 billion in fiscal 2027 revenue when it released its fiscal 2026 fourth-quarter results in March this year. Its fiscal 2028 guidance stood at $15 billion at that time, following a $2 billion upward revision from the December 2025 guidance. Investment banking firm RBC Capital Markets expects Marvell to increase guidance once again during its investor day presentation on Oct. 6.

Specifically, RBC expects Marvell to increase its fiscal 2029 AI revenue forecast by at least $2 billion from the current estimate of $10 billion. Additionally, RBC expects Marvell to substantially increase its total addressable market (TAM) guidance and 2030 market share estimates on Oct. 6.

The investment bank also estimates that an increase in Marvell's operating margins could propel its earnings per share (EPS) into the $15.00 to $20.00 range over the long run. That indeed seems possible, considering that Marvell's earnings are expected to jump by 48% in the current fiscal year to $4.21, followed by a significant acceleration in fiscal 2028 and another significant jump in fiscal 2029.

MRVL EPS Estimates for Current Fiscal Year data by YCharts

If Marvell delivers a stronger forecast for the next couple of fiscal years and raises its TAM estimate for 2030, driven by the healthy growth in custom AI processors and networking chips, it could win back investor confidence once again.

Though this AI stock has jumped by just over 3x in 2026, its shares have dropped 16% after reaching a 52-week high on June 18. Savvy investors should consider capitalizing on this pullback, as favorable management commentary could send Marvell on a bull run. Moreover, the strong long-term growth prospects indicate that Marvell could make investors significantly richer.

The stock can still doubleYou may be wondering if Marvell is worth buying following its stunning rally in 2026. The stock is expensive at 86 times trailing earnings and 62 times forward earnings. However, we have already seen that its earnings growth is poised to accelerate.

Assuming Marvell's earnings land between $15.00 and $20.00 per share in 2030, which seems quite possible given that its earnings per share could hit $10.45 in fiscal 2029 (which ends in January 2029), its stock could jump significantly from current levels. For instance, $17.50 in EPS could send Marvell stock to $525 even if it trades at 30 times earnings after four and a half years.

That's nearly double Marvell's stock price right now. So, investors looking to buy a top growth stock on the dip can consider buying Marvell Technology ahead of its investor day, when it could make a big move.

Investment reinforces Awayday's locally-run, field-first model and supports its commitment to delivering value to key stakeholders

, /PRNewswire/ -- Awayday (the "Company"), a leading vacation rental management company on a mission to perfect the vacation rental experience for owners and guests alike, today announced it has closed a significant investment from Warburg Pincus, the pioneer of global growth investing. The investment is being made by the Warburg Pincus Capital Solutions Founders Fund ("WPCS FF"). The Company's majority owners, an Ares Private Equity fund ("Ares") and LightBay Capital ("LightBay"), will remain the controlling shareholders. Terms of the investment were not disclosed.

Awayday partners with independent vacation rental operators seeking the scale, systems, and support of a national platform while preserving their local identity – an approach the Company calls "Join Us, Stay You." Today, the Company manages more than 18,000 properties across the United States through a portfolio of local brands, supported by more than 1,800 team members.

Awayday will use proceeds from this investment to return capital to the Company's existing equity investors, including Ares, LightBay, and its rollover equity partners. In addition, Awayday will deliver proceeds to the leading local operators and supporting team members who have been integral to driving the Company's growth through its field-first model.

"Warburg Pincus' investment is a vote of confidence in our team of more than 1,800 people – some of the most experienced local operators and support teams in the vacation rental industry – and in the strength of our portfolio of vacation rental brands across North America," said Jakob Dwyer, CEO of Awayday. "Ownership mentality is one of our core values: we ask our teams to think and act like owners, and we believe they should share in the value they create. At Awayday, we call that 'winning together' through a model that supports locally run businesses led by operators who put their guests, owners, and teams first. Our local teams are the stars of the show, and we will keep building a company that treats them that way."

"Awayday has built an exceptional vacation rental management company, rooted in a business model that combines national reach with local connections and expertise. That model has fueled both strong organic growth and a highly effective M&A strategy," said Lee Becker, Managing Director at Warburg Pincus. "This investment aligns with our strategy of partnering with market-leading businesses that deliver strong value for customers and employees, have a proven track record of organic growth, and are led by best-in-class leadership teams at every level of the organization. We look forward to supporting Awayday as it continues to build on its success to date," added Claire Branch, Principal at Warburg Pincus.

Warburg Pincus Capital Solutions Founders Fund closed in September 2024 with over $4 billion in commitments. Capital Solutions has a flexible mandate that allows it to partner with founders and existing shareholders to provide solutions for balance sheet optimization, shareholder liquidity, M&A, or growth. The group leverages Warburg Pincus' global platform and firmwide resources across geographies to source and execute on hybrid capital transactions.

About Awayday
Awayday is a national vacation rental management company on a mission to perfect the vacation rental experience. Awayday manages more than 18,000 properties across the United States through a portfolio of local brands, supported by more than 1,800 team members. Guided by its core values – Servant Leadership, Ownership Mentality, "Local, Local, Local", and Excellence – Awayday pairs national scale in technology, revenue management, and marketing with local teams who know their markets and care for their customers.

About Warburg Pincus
Warburg Pincus LLC is the pioneer of global growth investing. A private partnership since 1966, the firm has the flexibility and experience to focus on helping investors and management teams achieve enduring success across market cycles. Today, the firm has more than $105 billion in assets under management, and more than 225 companies in its active portfolio, diversified across stages, sectors, and geographies. Warburg Pincus has invested in more than 1,100 companies across its private equity, real estate, and capital solutions strategies.

Warburg Pincus' Capital Solutions team collaborates closely with the firm's 290+ investment professionals and 75+ value creation executives across Warburg Pincus' global industry verticals, critical to sourcing and underwriting differentiated, attractive investments. Recent investments have included DriveCentric, Excelitas Technologies, Global Eggs, MB2 Dental, Madison International Realty, MIAX, MyKaarma, Nord Security, Paradigm Oral Health, Service Compression, and United Trust Bank.

The firm is headquartered in New York with more than 15 offices globally. For more information, please visit www.warburgpincus.com or follow us on LinkedIn and YouTube.

About Ares Management Corporation
Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, real estate, private equity, and infrastructure asset classes. We seek to advance our stakeholders' long-term goals by providing flexible capital that supports businesses and creates value for our investors and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of June 30, 2026, Ares Management Corporation's global platform had over $671 billion of assets under management, with operations across North America, South America, Europe, Asia Pacific and the Middle East. For more information, please visit www.ares.com.

About LightBay Capital
LightBay Capital is a Los Angeles-based private equity firm with $1.7 billion of committed capital. We invest primarily in founder-led healthcare and business services companies, partnering with owners and their management teams to accelerate growth through investments in talent and technology. For more than two decades, LightBay's principals have created meaningful value by pairing deep domain expertise with a shared commitment to servant leadership and an entrepreneurial mindset. For more information, please visit www.lightbay.com

Media Contacts
Awayday
Danny Bradford
EVP of Revenue & Marketing
[email protected]

Warburg Pincus
Caroline Wise
[email protected]

SOURCE Warburg Pincus

, /PRNewswire/ -- Allison Transmission Holdings, Inc. (NYSE: ALSN) ("Allison" or the "Company") announced the completion of its partial redemption of $100 million aggregate principal amount of its 4.750% Senior Notes due 2027 (the "notes") on September 30, 2026 (the "redemption date"), pursuant to its optional redemption right under the indenture governing the notes, dated as of September 26, 2017.

On the redemption date, the notes were redeemed at a redemption price of 100.00% of the principal amount thereof plus accrued and unpaid interest to, but not including, the redemption date. Following the completion of the partial redemption, $300 million aggregate principal amount of the notes remain outstanding.

About Allison

Allison (NYSE: ALSN) is a global leader in high-performance mobility and work solutions built for the needs of the modern industrial world. Allison operates through two business units: Allison Transmission and Allison Off-Highway Drive & Motion Systems. Headquartered in Indianapolis, Indiana, USA, the Company manufactures solutions which offer industry-leading value propositions across vital sectors such as infrastructure, mining, energy, agriculture, construction, transportation and national security. For over 110 years, Allison has been recognized as a reliable partner of choice, keeping essential industries moving anytime, in over 150 countries around the world.

SOURCE Allison Transmission Holdings Inc.

MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) declares its monthly distribution for October 2026 of $0.0833 per share, comprised of an $0.08 per share base dividend and $0.0033 per share supplemental dividend, payable on November 2, 2026 to stockholders of record as of October 15, 2026. The distribution is expected to be paid from taxable net investment income. The final specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year and in the Company's periodic report filed with the Securities and Exchange Commission.

The Company, which operates as a regulated investment company (“RIC”), generates qualified interest income and short-term capital gains that may be exempt from U.S. withholding tax when distributed to non-U.S. stockholders. The U.S. tax law permits a RIC to report the portion of distributions paid that represents interest-related dividends as exempt from U.S. withholding tax when paid to non-U.S. stockholders with proper documentation.

The specific tax characteristics of this distribution can be found on our website www.pennantpark.com.

ABOUT PENNANTPARK FLOATING RATE CAPITAL LTD.

PennantPark Floating Rate Capital Ltd. is a business development company which primarily invests in U.S. middle-market private companies in the form of floating rate senior secured loans, including first lien secured debt, second lien secured debt and subordinated debt. From time to time, the Company may also invest in equity investments. PennantPark Floating Rate Capital Ltd. is managed by PennantPark Investment Advisers, LLC.

ABOUT PENNANTPARK INVESTMENT ADVISERS, LLC

PennantPark Investment Advisers, LLC, a leading middle market credit platform, and its affiliates, manage over $10 billion of investable capital, including potential leverage. Since its inception in 2007, PennantPark Investment Advisers, LLC has provided investors access to middle market credit by offering private equity firms and their portfolio companies as well as other middle-market borrowers a comprehensive range of creative and flexible financing solutions. PennantPark Investment Advisers, LLC is headquartered in Miami and has offices in New York, Chicago, Houston, Los Angeles, Amsterdam, and Zurich. For more information about PennantPark and affiliates, please go to our website at www.pennantpark.com.

FORWARD-LOOKING STATEMENTS

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. You should understand that under Section 27A(b)(2)(B) of the Securities Act and Section 21E(b)(2)(B) of the Exchange Act the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 do not apply to forward-looking statements made in periodic reports PennantPark Floating Rate Capital Ltd. files under the Exchange Act. All statements other than statements of historical facts included in this press release are forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in filings with the Securities and Exchange Commission. PennantPark Floating Rate Capital Ltd. undertakes no duty to update any forward-looking statement made herein. You should not place undue influence on such forward-looking statements as such statements speak only as of the date on which they are made.

The information contained herein is based on current tax laws, which may change in the future. The Company cannot be held responsible for any direct or incidental loss resulting from applying any of the information provided in this publication or from any other source mentioned. The information provided in this material does not constitute any specific legal, tax or accounting advice. Please consult with qualified professionals for this type of advice.

CONTACT:
Richard T. Allorto, Jr.
PennantPark Floating Rate Capital Ltd.
(212) 905-1000
www.pennantpark.com

The Federal Aviation Administration said Friday that it has determined a new software glitch on some Boeing 737 Max aircraft isn't a flight-safety issue.

The determination paves the way to certification for the last model in the company's best-selling family of airplanes, the 737 Max 10, just as Boeing seeking to sell and deliver more aircraft after years of safety and manufacturing crises.

Boeing flagged the software issue, which could affect certain landing procedures, last month and the FAA on Monday said it was reviewing to determine if it poses a safety of flight issue.

"Following a thorough review, a panel of FAA safety experts on Friday determined a software issue in certain Boeing 737 MAX flight computers is not a safety concern," the FAA said. "The FAA's Corrective Action Review Board made that determination because pilots retain full control of the aircraft and the indications to the flight crew are clear and unambiguous."

Boeing said the issue could arise after a missed approach when pilots alter a preprogrammed flight path, and that pilots must take additional steps to use automated tools on subsequent approaches.

The FAA said on Friday that it will issue a special bulletin to airlines on how to recognize and respond to the issue if it arises.

The agency convened a review board on Friday to assess the issue. Participants included FAA experts on airframes, flight controls, propulsion, flight testing and others.

"As with any situation, the FAA will consider appropriate action if it receives new information about this issue," the agency said.

U.S. airlines said they're not affected by the issue since they could revert to older versions of the software, but the problem raised questions about certification of the Boeing 737 Max 10, which Boeing and airlines expected to come in early fall.

The Max 10 is the largest in the family of airplanes and would be the last of the Max lineup to win government certification to fly. The FAA approved the Max 7, the smallest in the Max family, in August.

Chief executives of 737 Max 10 customers, Alaska Airlines and Ryanair, earlier this week brushed off concerns about the aircraft's certification delays.

Read more CNBC airline newsBudget airline king Bill Franke warms to premium upgradesCompanies spurn airlines’ cheapest business class ticketsUnited’s next decision: What to do with all those Boeing 737 Max 10 seats it ordered years agoWhy flights are so expensive and will likely stay that waySouthwest Airlines put Texas jet fuel on a boat to LA for the first time amid supply worriesRecord heat, crowds drive offseason boom in international travel

American Express
AXP +0.23% 89

, the card network and premium financial-services company, launched its revamped Amex Corporate platform on September 30, bringing cashback cards, expense software and AI capabilities into one package. Shares stood at $300.225 at 11.10am ET on October 2, down approximately 0.6%. The pitch is simple: make corporate spending easier to manage and give businesses more reasons to keep their payments with Amex.

The software connects card transactions with expense reporting, while the mobile app creates expense submissions as purchases happen. Businesses can also set rules governing where, when and how employees spend. According to PYMNTS, Amex plans to add AI agents later this year that chase missing expense details and answer finance teams' spending questions. Those planned agents give investors another milestone to watch; the launch alone does not establish how much additional business the platform will generate.

The investment case comes down to stickier customers and more spending flowing through Amex's network. Connecting payments and expense workflows could make switching providers more cumbersome, but competitors can add AI features too. The valuation snapshot puts shares 7.52% below the $324.63 GF Value estimate, suggesting a modest valuation cushion rather than proof of a bargain. Customer adoption, retention and payment growth will show whether this overhaul delivers more than a better interface.

Check the Warning Signs for

AXP

now!

Realty Income has handed out monthly dividends for decades and built a global property empire spanning casinos, data centers, and European real estate, yet patient long-term holders still trail the S&P 500 by a stunning margin. Whether the next decade…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A Strip-Mall Landlord Turned Global Property Giant Realty Income (NYSE:O) is a net lease REIT that owns single-tenant buildings where tenants pay most taxes, insurance, and maintenance. Rent and dividends come monthly, earning the nickname “The Monthly Dividend Company”.

A decade ago it was mostly a U.S. retail landlord. Mergers with VEREIT (2021) and Spirit Realty Capital (2024) expanded it to 15,542 properties across eight European countries plus Mexico. Industrial properties made up 65% of Q2 2026 new investment. It owns casino properties including Bellagio and announced a $6 billion hyperscale data center JV in 2026. Occupancy was 98.8%.

The monthly dividend grew from $0.202 in September 2016 to $0.2715 in September 2026, marking the company’s 115th consecutive quarterly dividend increase.

Dividends Turned a Price Loss Into a Gain All periods run from September month-end close to October 1, 2026 close, with reinvested dividends unless marked “price only.” S&P 500 figures include reinvested dividends.

1-Year Return

Initial Investment: $1,000 Current Value: $933.13 Total Return: -6.69% (price only: -11.94%) S&P 500 (same period): $1,159.18 (15.92%) 5-Year Return

Initial Investment: $1,000 Current Value: $1,103.92 Total Return: 10.39% (price only: -17.47%) Annualized Return: 2.00% S&P 500 (same period): $1,903.74 (90.37%) 10-Year Return

Initial Investment: $1,000 Current Value: $1,330.52 Total Return: 33.05% (price only: $799.79, or -20.02%) Annualized Return: 2.90% S&P 500 (same period): $4,138.75 (313.87%) Reinvested dividends added $530.73, turning a price loss into a gain. The stock fell from $78.41 in January 2020 to $38.00 intraday in March 2020, a 51.54% drop. Rising rates hurt further: the 10-year Treasury yield rose from 1.52% at end-2021 to 5.29% by September 30, 2026. Shares fell 35.96% from July 2022 to October 2023, then lost another 12.32% in the past month.

I’m Waiting for Treasury Yields to Crack The case for Realty Income improves if long-term rates have topped out and weakens if the 10-year Treasury yield remains above 5%.

The bull case: The stock yields 5.77% and the company carries an “A” rating from Fitch. Management raised 2026 adjusted funds from operations (AFFO, a REIT cash-earnings measure) guidance to $4.44 to $4.45 per share and investment guidance to $10.0B. Its private capital funds also reduce how often it has to sell new shares to fund deals.

The bear case: AFFO growth is running at about 4%. Tenants without investment-grade credit account for 65.7% of base rent, and the watch list remains in the high 5% range. Treasuries now pay close to the stock’s yield, with no credit risk.

Can the next decade match the last? Possibly, but that means low-to-mid single-digit total returns depending mostly on dividends, still trailing the S&P 500. Falling Treasury yields are the key signal to watch.

Contact [email protected] for any questions or corrections.

Palantir Technologies
PLTR -0.39% 83

, the defense and enterprise-AI software company, named Armada its first certified modular data-center partner, with shares up approximately 1.82% to $193.505 at 11.05am ET on October 2. The partnership targets governments and businesses that want control over their AI infrastructure. The valuation graphic puts the stock 5.78% above its $182.93 GF Value™, suggesting investors already price in some growth upside.

The offering brings Palantir's sovereign-AI software together with Armada's modular data centers and infrastructure-management tools. According to Financial News, the hardware will be manufactured in the United States and allied countries. Customers would run models on infrastructure they own and control. The companies disclosed no contract value, purchase commitment, customer count or revenue-sharing terms.

For Palantir, the opportunity is to make its software easier to deploy where data security, equipment origin and local control shape purchasing decisions. An integrated package could reduce the work customers face stitching together separate systems. But certification does not put dollars into backlog by itself. The next meaningful proof is paying customers—and evidence that deployments turn into recurring software revenue.

Check the Warning Signs for

PLTR

now!

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. This approval allows for the use of Jaypirca as a first-line treatment for appropriate patients.

"This approval is grounded in data from BRUIN CLL-313, which showed a significant delay in disease progression for pirtobrutinib compared to chemoimmunotherapy, along with safety and tolerability consistent with its established profile," said Jennifer A. Woyach, M.D., professor, hematologist-oncologist, and Director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. "Doctors can now consider pirtobrutinib for appropriate patients when initial therapy is needed, not just later in a patient's treatment journey. Given the efficacy and tolerability of modern targeted therapies – coupled with factors like age or comorbidity – many people diagnosed with CLL or SLL today may only receive one or two lines of therapy, making initial treatment choices critically important."

The labeling for Jaypirca contains warnings and precautions for infections, hemorrhage, cytopenias, cardiac arrhythmias, second primary malignancies, hepatotoxicity including drug-induced liver injury and embryo-fetal toxicity. See Important Safety Information below and full Prescribing Information for additional information, including dosing modifications.

Jaypirca, the first-and-only FDA-approved non-covalent BTK inhibitor, is a highly selective kinase inhibitor that utilizes a novel non-covalent binding mechanism to target the BTK pathway in patients with CLL/SLL.1,2

The FDA approval is based on results from the primary analysis of the BRUIN CLL-313 clinical trial, which were presented at the American Society of Hematology Annual Meeting and Exposition in December 2025 and published in The Journal of Clinical Oncology.3  BRUIN CLL-313 is the first prospective, randomized Phase 3 study to examine the efficacy and safety of a non-covalent BTK inhibitor in patients with previously untreated CLL/SLL without 17p deletion.

In BRUIN CLL-313, at a median follow-up of 28 months, the primary endpoint of Independent Review Committee (IRC)-assessed progression-free survival (PFS) was significantly improved with pirtobrutinib (n=141) compared to bendamustine plus rituximab (BR) (n=141) (HR=0.20 [95% CI, 0.11–0.37]; p<0.0001), and the median PFS was not yet reached for pirtobrutinib compared to 33.5 months for BR.4 IRC-assessed overall response rate (ORR) was 94% (95% CI, 89–98) in the pirtobrutinib arm (complete response [CR]=13%; partial response [PR]=81%) and 81% (95% CI, 73–87) in the BR arm (CR=21%; PR=60%). In the BRUIN CLL-313 trial, adverse reactions (ARs) led to dose reductions in 3.6% and permanent discontinuation of Jaypirca in 4.3% of patients. Serious ARs occurred in 28% of patients who received Jaypirca. Serious ARs occurring in ≥3% of patients included pneumonia (5%). The overall safety profile, including rates of atrial fibrillation or flutter, for patients treated with pirtobrutinib in the BRUIN CLL-313 trial was consistent with previously reported trials across treatment settings.

"This additional approval for Jaypirca, based on BRUIN CLL-313, marks a significant step forward, expanding its potential to reach more patients who may benefit – this time as an initial treatment for certain previously untreated patients with CLL or SLL," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "This milestone underscores Jaypirca's versatility in the CLL continuum of care, from the first-line setting for appropriate patients to its valuable role in the relapsed or refractory post-covalent BTK inhibitor setting, reinforcing Jaypirca's broad applicability as a meaningful treatment option for people with CLL or SLL."

Jaypirca is the first-and-only non-covalent BTK inhibitor recommended by the National Comprehensive Cancer Network® (NCCN®).1,5,6,7 Jaypirca is Category 2A recommended for treatment-naïve adult patients with CLL/SLL without del(17p), recommended for older patients with cardiac comorbidities who may only need one lifetime treatment for CLL/SLL.8 Jaypirca is a Category 1 preferred option for adult patients with relapsed or refractory CLL/SLL who have previously been treated with a covalent BTK inhibitor. Please see full NCCN guidelines for more information.

Lilly is studying Jaypirca in CLL/SLL in multiple Phase 3 studies. Details on the trials can be found by visiting clinicaltrials.gov.

See Important Safety Information below and full Prescribing Information for additional information.

Click here to view the CLL infographic.

About the BRUIN Clinical Development Program
The BRUIN clinical development program comprises four positive Phase 3 studies evaluating pirtobrutinib across multiple lines of CLL/SLL:

BRUIN CLL-313 is the first prospective, randomized Phase 3 study to examine the efficacy and safety of a non-covalent BTK inhibitor in patients with previously untreated CLL without 17p deletion. The BRUIN CLL-313 study is evaluating pirtobrutinib versus chemoimmunotherapy (BR) in patients with CLL/SLL without 17p deletion who have not been previously treated. BRUIN CLL-314 is the first head-to-head Phase 3 CLL trial to compare covalent and non-covalent BTK inhibitors in a BTKi-naïve population, which included relapsed and refractory and treatment-naïve patients. The BRUIN CLL-314 study is evaluating pirtobrutinib versus ibrutinib in patients with CLL/SLL who were either treatment-naïve, or who were previously treated and were BTK inhibitor-naïve. BRUIN CLL-321 is the first randomized Phase 3 study in CLL in which all patients were previously treated with a covalent BTK inhibitor. The BRUIN CLL-321 study is evaluating pirtobrutinib versus investigator's choice of idelalisib plus rituximab (IdelaR) or BR in covalent BTK inhibitor pre-treated patients with relapsed and refractory CLL/SLL. BRUIN CLL-322 is the first Phase 3 readout in CLL to utilize a venetoclax-containing control arm. The BRUIN CLL-322 study is evaluating time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated CLL/SLL patients. About BRUIN CLL-313
BRUIN CLL-313 (NCT05023980) is a Phase 3, global, randomized, open-label study of Jaypirca (pirtobrutinib) versus chemoimmunotherapy (BR) in people with CLL/SLL without 17p deletion who have not been previously treated. The trial enrolled 282 patients who were randomized 1:1 to receive pirtobrutinib (200 mg orally, once daily until disease progression or unacceptable toxicity) or BR per labeled doses. BR is a chemoimmunotherapy regimen used in the treatment of CLL. The primary endpoint is PFS as assessed by blinded IRC. Secondary endpoints include investigator and IRC-assessed ORR and duration of response (DoR), investigator-assessed PFS, overall survival (OS), time to next treatment (TTNT), safety and tolerability and patient-reported outcomes (PRO).

About Jaypirca (pirtobrutinib)
Jaypirca (pirtobrutinib, formerly known as LOXO-305) (pronounced jay-pihr-kaa) is a highly selective (300 times more selective for BTK versus 98% of other kinases tested in preclinical studies), non-covalent inhibitor of the enzyme BTK, and is the first-and-only approved non-covalent BTK inhibitor binding to both wild-type and C481 mutated BTK.2 BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).9,10 Jaypirca is a U.S. FDA-approved oral prescription medicine, 100 mg or 50 mg tablets taken as a once-daily 200 mg dose with or without food until disease progression or unacceptable toxicity.

About Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CLL and SLL are forms of slow-growing non-Hodgkin lymphoma that develop from white blood cells known as lymphocytes.11 CLL is one of the most common types of leukemia in adults.11 In the U.S., CLL accounts for about one-quarter of the new cases of leukemia and there will be approximately 22,760 new cases of CLL diagnosed this year.11,12 SLL is identical to CLL from a pathologic and immunophenotypic standpoint, with the main difference between them being the location of the cancer cells.11 In CLL, the cancer cells are present in the blood, and in SLL, the cancer cells are found in the lymph nodes.11

INDICATIONS FOR JAYPIRCA (pirtobrutinib)
Jaypirca is indicated for the treatment of:

Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor. Adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. Adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. IMPORTANT SAFETY INFORMATION FOR JAYPIRCA (pirtobrutinib)

Infections: Fatal and serious infections (including bacterial, viral, fungal) and opportunistic infections occurred in Jaypirca-treated patients. Across all clinical trials, Grade ≥3 infections occurred (23%), most commonly pneumonia (13%); fatal infections (4.3%), sepsis (4.8%), and febrile neutropenia (3.3%) occurred. In patients with CLL/SLL, Grade ≥3 infections occurred (24%), with fatal infections occurring in 5%. Opportunistic infections included Pneumocystis jirovecii pneumonia and fungal infection. Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients at increased risk for infection, including opportunistic infections. Monitor for signs and symptoms, evaluate, and treat. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.

Hemorrhage: Fatal and serious hemorrhage has occurred with Jaypirca. Across all clinical trials, major hemorrhage (Grade ≥3 bleeding or any central nervous system bleeding) occurred (3.1%), including gastrointestinal hemorrhage; fatal hemorrhage occurred (0.3%). Bleeding of any grade, excluding bruising and petechiae, occurred (18%). Major hemorrhage occurred when taking Jaypirca with (1.3%) and without (1.8%) antithrombotic agents. Consider risks/benefits of coadministering antithrombotic agents with Jaypirca. Monitor for signs of bleeding. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca. Consider withholding Jaypirca 3-7 days pre- and post-surgery based on surgery type and bleeding risk.

Cytopenias: Jaypirca can cause cytopenias, including neutropenia, thrombocytopenia, and anemia. Across all clinical trials, Grade 3 or 4 cytopenias, including decreased neutrophils (26%), decreased platelets (9%), and decreased hemoglobin (9%), developed. Grade 4 decreased neutrophils (14%) and Grade 4 decreased platelets (4.3%) developed. Monitor complete blood counts regularly. Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.

Cardiac Arrhythmias: Cardiac arrhythmias occurred in patients taking Jaypirca. Across all clinical trials, atrial fibrillation or flutter were reported in 3.1% of Jaypirca-treated patients, with Grade 3 or 4 atrial fibrillation or flutter in 1.6%. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred (0.3%). Cardiac risk factors such as hypertension or previous arrhythmias may increase risk. Monitor and manage signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea). Based on severity, reduce dose, temporarily withhold, or permanently discontinue Jaypirca.

Second Primary Malignancies: Across all clinical trials, second primary malignancies, including non-skin carcinomas, developed in 10% of Jaypirca-treated patients, most frequently non-melanoma skin cancer (4.9%). Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor for development of second primary malignancies.

Hepatotoxicity, Including Drug-Induced Liver Injury (DILI): Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of DILI, has occurred in patients treated with BTK inhibitors, including Jaypirca. Evaluate bilirubin and transaminases at baseline and throughout Jaypirca treatment. For patients who develop abnormal liver tests after Jaypirca, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold Jaypirca. If DILI is confirmed, discontinue Jaypirca.

Embryo-Fetal Toxicity: Jaypirca can cause fetal harm. Administration of pirtobrutinib to pregnant rats caused embryo-fetal toxicity, including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended 200 mg once daily dose. Advise pregnant women of fetal risk and females of reproductive potential to use effective contraception during treatment and for one week after last dose.

Adverse Reactions (ARs) in Patients Who Received Jaypirca

The most common (≥30%) ARs in the pooled safety population of patients with hematologic malignancies (n=1153) were decreased neutrophil count (56%) and decreased hemoglobin (38%).

Mantle Cell Lymphoma

Serious ARs occurred in 38% of patients, with pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%) occurring in ≥2% of patients. Fatal ARs within 28 days of last dose occurred in 7% of patients, most commonly due to infections (4.7%), including COVID-19 (3.1% of all patients).

Dose Modifications and Discontinuations Due to ARs: Dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of Jaypirca in 9% of patients. Permanent discontinuation in >1% of patients included pneumonia.

Most common ARs (≥15%) and Select Laboratory Abnormalities (≥10%) (all Grades %; Grade 3 or 4%): hemoglobin decreased (42; 9), platelet count decreased (39; 14), neutrophil count decreased (36; 16), lymphocyte count decreased (32; 15), creatinine increased (30; 1.6), fatigue (29; 1.6), musculoskeletal pain (27; 3.9), calcium decreased (19; 1.6), diarrhea (19; -), edema (18; 0.8), dyspnea (17; 2.3), AST increased (17; 1.6), pneumonia (16; 14), bruising (16; -), potassium decreased (13; 1.6), sodium decreased (13; -), lipase increased (12; 4.4), ALT increased (11; 1.6), potassium increased (11; 0.8), alkaline phosphatase increased (11; -). Grade 4 laboratory abnormalities in >5% of patients included neutrophils decreased (10), platelets decreased (7), lymphocytes decreased (6).

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma from Single-Arm and Randomized Controlled Clinical Trials

Serious ARs occurred in 28-56% of patients across clinical trials. Serious ARs in ≥5% of patients in the single-arm trial were pneumonia (18%), COVID-19 (9%), sepsis (7%), febrile neutropenia (7%). Serious ARs in ≥3% of patients in the randomized controlled trials were pneumonia (5-21%), COVID-19 (5%), sepsis (3.4%). Across clinical trials, fatal ARs within 28-30 days of last Jaypirca dose occurred in 0.7-11% of patients, most commonly due to infections (7-10%), including sepsis (5%), COVID-19 (2.7-5%), pneumonia (3.4%) and septic shock (0.7%).

Dose Modifications and Discontinuations Due to ARs: Dose reductions in 3.6-10%, treatment interruption in 35-51%, and permanent discontinuation of Jaypirca in 4.3-17% of patients. Permanent discontinuation in >1% of patients included second primary malignancy, pneumonia, COVID-19, neutropenia, sepsis, anemia, and cardiac arrhythmias.

Most common ARs and Select Laboratory Abnormalities (≥20%) (all Grades %, Grade 3 or 4%)—across randomized controlled trials: neutrophil count decreased (48-54; 14-26), hemoglobin decreased (24-45; 6-10), platelet count decreased (37; 17), upper respiratory tract infections (21-27; 0.9-2.1), bilirubin increased (21-30; 0.9-5), pneumonia (28; 16), ALT increased (25-27; 1.8-2.9), creatinine increased (25; -), calcium decreased (23; 0.9), sodium decreased (22; 0.9), rash (22; 0.7), COVID-19 (21; 0.7), sodium increased (20; -); in a single-arm trial: neutrophil count decreased (63; 45), hemoglobin decreased (48; 19), calcium decreased (40; 2.8), fatigue (36; 2.7), bruising (36; -), cough (33; -), musculoskeletal pain (32; 0.9), platelet count decreased (30; 15), sodium decreased (30; -), COVID-19 (28; 7), pneumonia (27; 16), diarrhea (26; -), abdominal pain (25; 2.7), lymphocyte count decreased (23; 8), ALT increased (23; 2.8), AST increased (23; 1.9), creatinine increased (23; -), dyspnea (22; 2.7), hemorrhage (22; 2.7), lipase increased (21; 7), alkaline phosphatase increased (21; -), edema (21; -), nausea (21; -), pyrexia (20; 2.7), headache (20; 0.9). Grade 4 laboratory abnormalities in >5% of patients included neutrophils decreased (23).

Drug Interactions

Strong CYP3A Inhibitors: Concomitant use increased pirtobrutinib systemic exposure, which may increase risk of Jaypirca ARs. Avoid using strong CYP3A inhibitors with Jaypirca. If concomitant use is unavoidable, reduce Jaypirca dose according to approved labeling.

Strong or Moderate CYP3A Inducers: Concomitant use decreased pirtobrutinib systemic exposure, which may reduce Jaypirca efficacy. Avoid using Jaypirca with strong or moderate CYP3A inducers. If concomitant use with moderate CYP3A inducers is unavoidable, increase Jaypirca dose according to approved labeling.

Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: Use with Jaypirca increased their plasma concentrations, which may increase risk of ARs related to these substrates for drugs sensitive to minimal concentration changes. Follow recommendations for these sensitive substrates in their approved labeling.

Use in Specific Populations

Pregnancy and Lactation: Due to potential for Jaypirca to cause fetal harm, verify pregnancy status in females of reproductive potential prior to starting Jaypirca. Presence of pirtobrutinib in human milk is unknown. Advise women to use effective contraception and to not breastfeed while taking Jaypirca and for one week after last dose.

Geriatric Use: In the pooled safety population of patients with hematologic malignancies, patients aged ≥65 years experienced higher rates of Grade ≥3 ARs and serious ARs compared to patients <65 years of age.

Renal Impairment: Because severe renal impairment increases pirtobrutinib exposure, reduce Jaypirca dose in these patients according to approved labeling.

PT HCP ISI MCL_CLL OCT2026

Please see Prescribing Information and Patient Information for Jaypirca.

Frequently Asked Questions 

1. What is Jaypirca (pirtobrutinib)?

Jaypirca (pirtobrutinib) is a highly selective kinase inhibitor that is 300 times more selective for Bruton tyrosine kinase (BTK) versus 98% of other kinases tested in preclinical studies.2 Jaypirca is the first-and-only approved non-covalent BTK inhibitor binding to both wild-type and C481 mutated BTK.2 BTK is a validated molecular target found across numerous B-cell leukemias and lymphomas including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).9,10 The FDA approved Jaypirca as a monotherapy for the treatment of adult patients with previously untreated CLL or small lymphocytic lymphoma (SLL) with no known 17p deletion in October 2026.

2. What is chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)?

CLL and SLL are forms of slow-growing non-Hodgkin lymphoma that develop from white blood cells called lymphocytes.11 CLL and SLL are considered different forms of the same disease and share the same pathologic and immunophenotypic characteristics.11 The primary difference between CLL and SLL is where the cancer cells are located.11 In CLL, the cancer cells are found primarily in the blood, while in SLL, the cancer cells are found primarily in the lymph nodes.11 CLL is one of the most common forms of leukemia in adults and accounts for approximately one-quarter of new leukemia diagnoses in the United States.11 An estimated 22,760 people in the U.S. will be diagnosed with CLL this year.12

3. What is chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion?

For people with CLL or SLL, certain cytogenic factors may be associated with a higher risk of disease progression.11 One of these factors is a deletion in chromosome 17 [del(17p)] that is found in about 5% to 8% of patients with CLL/SLL when they are first diagnosed.11,13 Del(17p) typically affects the tumor protein p53 (TP53) tumor suppressor gene.11

4. As the basis of this approval, what are the clinical benefits of Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion?

In the Phase 3 BRUIN CLL-313 study, pirtobrutinib significantly improved Independent Review Committee (IRC)-assessed progression-free survival (PFS) compared to bendamustine plus rituximab (BR) (HR=0.20 [95% CI, 0.11–0.37]; p<0.0001) in patients with previously untreated CLL/SLL without 17p deletion, and the median PFS was not yet reached for pirtobrutinib compared to 33.5 months for BR.4  IRC-assessed overall response rate (ORR) was 94% (95% CI, 89–98) in the pirtobrutinib arm (complete response [CR]=13%; partial response [PR]=81%) and 81% (95% CI, 73–87) in the BR arm (CR=21%; PR=60%).

5. What are the safety results for Jaypirca (pirtobrutinib) from the BRUIN CLL-313 trial?

The overall safety profile, including rates of atrial fibrillation or flutter, for patients treated with pirtobrutinib in the BRUIN CLL-313 trial was consistent with previously reported trials across treatment settings. In the BRUIN CLL-313 trial, in patients with previously untreated CLL/SLL without 17p deletion, a low rate of all-grades atrial fibrillation or flutter was observed, occurring in 1.4% of patients taking pirtobrutinib. Median duration of treatment with pirtobrutinib was 32 months with 92% on treatment for greater than 24 months. Clinically relevant adverse reactions in <10% of patients who received pirtobrutinib include pneumonia and headache. Patients with significant cardiovascular disease (including uncontrolled or symptomatic arrhythmias) were excluded from the CLL-313 study, and the Prescribing Information for Jaypirca includes a Cardiac Arrhythmias warning/precaution. The all-grades adverse reactions ≥20% reported for patients treated with Jaypirca were upper respiratory tract infection (27%), rash (22%), COVID-19 including COVID-19 pneumonia (21%). Select all-grades laboratory abnormalities (≥20%) that worsened from baseline were neutrophil count decreased (48%), bilirubin increased (30%), ALT increased (27%), hemoglobin decreased (24%), and sodium increased (20%).

6. How does this indication for Jaypirca (pirtobrutinib) differ from the previously approved indication for patients with CLL in the U.S.?

In December 2025, the U.S. Food and Drug Administration (FDA) granted approval to Jaypirca (pirtobrutinib) for the treatment of adults with relapsed or refractory CLL or SLL who have previously been treated with a covalent BTK inhibitor. This prior FDA action expanded the Jaypirca label to include patients earlier in their treatment course and converted the December 2023 accelerated approval for later-line CLL/SLL to a traditional approval. This new approval in the U.S. authorizes Jaypirca for adult patients with previously untreated CLL/SLL with no known 17p deletion. This expanded indication brings Jaypirca to the first-line CLL/SLL setting for certain previously untreated patients.

7. Is Jaypirca (pirtobrutinib) approved for 1L CLL treatment?

Yes, Jaypirca (pirtobrutinib) is approved for adult patients with previously untreated CLL/SLL patients with no known 17p deletion. For appropriate patients starting treatment, physicians may consider Jaypirca in 1L CLL.

8. How is Jaypirca (pirtobrutinib) different than ibrutinib, acalabrutinib and zanubrutinib?

Jaypirca (pirtobrutinib) is the first-and-only approved non-covalent BTK inhibitor, representing a newer class of BTK inhibitor compared to ibrutinib, acalabrutinib, and zanubrutinib which are all covalent BTK inhibitors. Based on preclinical studies, pirtobrutinib is different in where and how it binds to the BTK protein in the adenosine triphosphate (ATP) pocket. There are no data from trials between Jaypirca and covalent BTK inhibitors comparing the clinical significance of their different binding mechanisms.

9. Is Jaypirca (pirtobrutinib) recommended in the NCCN® Guidelines?

Jaypirca (pirtobrutinib) is the first-and-only non-covalent BTK inhibitor recommended by the National Comprehensive Cancer Network® (NCCN®).1,5,6,7 Jaypirca is Category 2A recommended for treatment-naïve adult patients with CLL/SLL without del(17p), recommended for older patients with cardiac comorbidities who may only need one lifetime treatment for CLL/SLL.8 Jaypirca is a Category 1 preferred option for adult patients with R/R CLL/SLL who have previously been treated with a covalent BTK inhibitor. Please see full NCCN guidelines for more information.

10. In which Phase 3 clinical trials is Jaypirca (pirtobrutinib) being studied in CLL and SLL?

Jaypirca (pirtobrutinib) is currently being studied in four Phase 3 clinical trials in CLL and SLL:

BRUIN CLL-321 (NCT04666038) is a Phase 3 open-label, randomized study of pirtobrutinib (LOXO-305) versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated CLL/SLL. More information on the BRUIN CLL-321 study can be found on clinicaltrials.gov. BRUIN CLL-322 (NCT04965493) is a Phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated CLL/SLL. More information on the BRUIN CLL-322 study can be found on clinicaltrials.gov. BRUIN CLL-313 (NCT05023980) is a Phase 3 open-label, randomized study of pirtobrutinib versus bendamustine plus rituximab in untreated patients with CLL. More information on the BRUIN CLL-313 study can be found on clinicaltrials.gov. BRUIN CLL-314 (NCT05254743) is a Phase 3 open-label, randomized study of pirtobrutinib versus ibrutinib in patients with CLL/SLL. More information on the BRUIN CLL-314 study can be found on clinicaltrials.gov. 11. What makes BRUIN CLL-313 different from other CLL trials?

BRUIN CLL-313 (NCT05023980) is the first Phase 3 study to evaluate a non-covalent BTK inhibitor in patients with previously untreated CLL without 17p deletion.

12. With this approval, how many people living with CLL may now be eligible for treatment with Jaypirca (pirtobrutinib)?

There are roughly 23,000 new cases of CLL in the U.S. each year, and approximately 92% to 95% of patients diagnosed with CLL do not have a 17p deletion.12,13 The majority of treated patients with CLL will receive a BTK therapy at some point in their treatment, with many patients today receiving potentially only one or two lines of therapy throughout their entire treatment journey.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

CMAT-52809 10/2026

© Lilly USA, LLC 2026. ALL RIGHTS RESERVED.

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Jaypirca (pirtobrutinib), as a treatment for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion, adult patients with relapsed or refractory CLL/SLL who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor and as a treatment for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that Jaypirca will receive additional regulatory approvals, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Endnotes & References

Jaypirca. Prescribing Information. Lilly USA, LLC. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892-901. doi:10.1016/S0140-6736(21)00224-5 Jurczak W, Kwiatek M, Czyz J, et al. BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. J Clin Oncol. 2026;44(6):466-475. doi:10.1200/JCO-25-02380 Based on Kaplan-Meier estimation. Lilly does not recommend use outside of its approved indications. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.6 To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN Defines: Category 1: Based upon high-level evidence (≥1randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate. Preferred intervention: interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V2.2027 ©National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed September 30, 2026. To view the most recent and complete version of the guidelines, go online to NCCN.org NCCN Category recommendations for pirtobrutinib do not differ based on del(17p) and/or TP53 mutation status. There are no available data on optimal sequencing of therapy for patients with disease progression on pirtobrutinib and development of cross resistance to covalent BTK inhibitor. Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186/s13045-020-00914-1 Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. J Hematol Oncol. 2021;14(1):40. Published 2021 Mar 6. doi:10.1186/s13045-021-01049-7 Mukkamalla SKR, Taneja A, Malipeddi D, et al. Chronic Lymphocytic Leukemia. [Updated 2023 Feb 18]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433/ National Cancer Institute. Cancer Stat Facts: Leukemia — Chronic Lymphocytic Leukemia (CLL). https://seer.cancer.gov/statfacts/html/clyl.html Hallek M. Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy. Am J Hematol. 2025;100(3):450-480. doi:10.1002/ajh.27546 SOURCE Eli Lilly and Company

Lennar Corp. (NYSE:LEN) shares are trading lower Friday afternoon after investigative outlet Hunterbrook Media published a short report alleging the homebuilder met quarterly targets by selling hundreds of finished homes to its own spinoff, Millrose Properties Inc. (NYSE:MRP). Benzinga reached out to Lennar for comment on the allegations but did not immediately hear back from the company.

Here’s what investors need to know.

Lennar stock is under selling pressure. Why is LEN stock trading lower? Hunterbrook Accuses Lennar of Offloading Homes to SpinoffAccording to the report, Millrose, spun off by Lennar in 2025 as an off-balance-sheet land bank, amended its agreements in late August to buy finished single-family homes and operate them as rental properties. Hunterbrook identified over 700 home purchases by Millrose totaling approximately $200 million across 15 states in roughly a month.

Notably, at least 356 of those purchases occurred in the final week of Lennar’s fiscal third quarter. Hunterbrook claims these transactions enabled Lennar to meet its quarterly delivery guidance, beating the lower bound by just 340 homes while missing its four other financial targets.

Financial Risk and Governance ConcernsHunterbrook Capital, which holds short positions in both Lennar and Millrose, highlighted severe economic inefficiencies in the arrangement. The report estimates Millrose’s net rental yield at around 5%, failing to cover its borrowing costs of 6.5% to 6.75%.

Furthermore, property records indicate Millrose paid roughly 13% more than individual retail buyers after accounting for incentives. With Lennar CEO Stuart Miller holding 43% of Millrose’s voting power, accounting experts cited in the report questioned whether Millrose is acting against its independent financial interest to bolster Lennar.

LEN Shares Drop Friday AfternoonLEN Price Action: Lennar shares were down 2.51% at $80.05 at the time of publication on Friday, according to Benzinga Pro data.

Read Next

Image: Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Shares of Super Micro Computer
SMCI +4.25% 85

climbed about 3% in Friday morning trading as investors focused on the server maker's expanding role in AI data-center deployments, following its latest rollout of Nvidia-powered rack systems.

Supermicro said it has started shipping Vera Rubin NVL72 systems through its Data Center Building Block Solutions platform. The racks pair 72 Rubin GPUs with 36 Vera CPUs and use direct liquid cooling designed for high-density computing environments.

The company's broader order pipeline is also drawing attention. Supermicro received more than $60 billion of orders in fiscal fourth quarter 2026 and expects fiscal 2027 revenue of $65 billion to $72 billion, according to Zacks Research.

Supermicro said its infrastructure can be deployed from five-megawatt projects to data centers operating at gigawatt scale. Its manufacturing network is being expanded across the United States, Taiwan, Malaysia and the Netherlands, with monthly capacity expected to exceed 6,000 racks.

Shares remain volatile, with the stock recently trading near $43.03. Investors are also watching margins and cash-flow conversion as the company expands to meet AI infrastructure demand.

Check the Warning Signs for

SMCI

now!

It has been about a month since the last earnings report for Ollie's Bargain Outlet (OLLI - Free Report) . Shares have added about 19.3% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Ollie's Bargain Outlet due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its latest earnings report in order to get a better handle on the important drivers.

OLLI Q2 Earnings Beat Estimates on Tariff Refunds, Sales MissOllie’s Bargain Outlet Holdings, Inc. reported second-quarter fiscal 2026 adjusted earnings of $1.42 per share, which improved 43.4% year over year and beat the Zacks Consensus Estimate of $1.14 by 24.6%. Net sales rose 9.1% to $741.3 million but missed the consensus mark of $753 million by 1.5%. Earnings benefited from IEEPA tariff refunds and lower tariff rates, while the sales increase reflected new-store growth. Comparable-store sales declined 1.8% as average basket size fell, with less favorable weather, consumer pressure and a heightened promotional environment weighing on demand.

OLLI’s Sales Growth Faces Comp PressureOLLI opened 15 stores and closed one storm-damaged location during the quarter, ending with 686 stores across 36 states. The store base increased 11.9% from a year earlier and remained the main driver of top-line growth. The company opened 42 stores in the first half of fiscal 2026. Comparable-store transactions were flat, while the average basket declined. Toys, general merchandise, summer furniture, candy and seasonal decor were the strongest categories. Lawn and garden plus room air represented more than 100 basis points of year-over-year comp pressure, with management indicating that the broader drag was more meaningful because those categories also drive store traffic.

Ollie’s Bargain Sees Mixed Consumer TrendsOllie’s Bargain said lower-income customers continued to prioritize needs over wants, shop closer to need and make fewer trips. Management defined that cohort at a household income of $65,000 or below. Higher-income customers, defined around $100,000 and above, continued to trade down in search of value. Ollie’s Army loyalty membership increased 12.7% to 18.1 million. New customer acquisition also increased, while management highlighted continued momentum among shoppers ages 35 to 55, with particular strength in the 35-45 range. Closeout deal flow remained strong, giving the retailer flexibility to adjust category mix and value.

OLLI’s Margins Get a Tariff Refund BoostGross margin expanded 360 basis points to 43.5%. IEEPA tariff refunds contributed 380 basis points, while merchandise margin declined primarily because of price investments. Lower tariff rates more than offset elevated transportation costs. Excluding the refund and related price investment, management said gross margin would have been about 40.3%-40.4%.

SG&A expenses increased 80 basis points as a share of sales to 26.6%, reflecting fixed-cost deleverage from the negative comp and higher marketing costs tied to one additional merchandise flyer. Pre-opening expenses fell 42% to $5.2 million on fewer store openings and lower dark-rent expense.

Ollie’s Bargain Posts Higher ProfitabilityAdjusted net income increased 40.3% to $85.4 million. Operating income rose 40.9% to $108.5 million, while adjusted EBITDA climbed 35.5% to $127.1 million. Adjusted EBITDA margin widened 330 basis points to 17.1%.

Beyond the tariff benefit, management cited favorable shrink trends and supply-chain efficiencies as additional support to earnings. The Texas distribution-center expansion was completed during the quarter, and operations have normalized. The Illinois facility expansion is expected to begin in the coming months.

OLLI Leverages Balance Sheet to Fund Growth and BuybacksTotal cash and investments reached $507.1 million, up 10.2% year over year, while inventories increased 10.5% to $704.4 million, primarily to support new-store growth. Capital expenditures totaled $43.3 million, with spending focused on new stores, existing-store improvements and the Texas distribution-center expansion.

OLLI repurchased about $84 million of stock in the quarter and $137.3 million in the first half. The company had $121.5 million remaining under its authorization at quarter-end and continued to carry no meaningful long-term debt.

Ollie’s Bargain Resets Sales View, Raises Profit GuideOllie’s Bargain lowered its fiscal 2026 net sales outlook to $2.928-$2.941 billion from $2.980-$3.000 billion. Comparable-store sales are now expected to range from flat to up 0.5%, down from the prior view of about 2% growth. The 75-store opening target was maintained, while planned share repurchases increased to about $175 million from $125 million.

The company raised its adjusted earnings outlook to $4.57-$4.65 per share from $4.45-$4.55 and lifted the gross-margin view to about 41.3% from 40.7%. Operating income is now projected at $345-$350 million. Management expects third-quarter comps near flat and fourth-quarter comps up about 1%, while August trends were running ahead of the plan used to set guidance.

How Have Estimates Been Moving Since Then?It turns out, estimates review have trended downward during the past month.

The consensus estimate has shifted -7.99% due to these changes.

VGM ScoresAt this time, Ollie's Bargain Outlet has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a score of C on the value side, putting it in the middle 20% for value investors.

Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Interestingly, Ollie's Bargain Outlet has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerOllie's Bargain Outlet belongs to the Zacks Consumer Products - Staples industry. Another stock from the same industry, BJ's Wholesale Club (BJ - Free Report) , has gained 1.3% over the past month. More than a month has passed since the company reported results for the quarter ended July 2026.

BJ's reported revenues of $6.09 billion in the last reported quarter, representing a year-over-year change of +13.2%. EPS of $1.36 for the same period compares with $1.14 a year ago.

BJ's is expected to post earnings of $1.22 per share for the current quarter, representing a year-over-year change of +5.2%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.1%.

The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for BJ's. Also, the stock has a VGM Score of A.

Applied Optoelectronics has surged 231% this year and just posted 86% revenue growth, yet the company is still losing money and one bad quarter could unwind months of gains. Here is what investors need to weigh before chasing the hottest…

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

The optics trade is running hot again. Applied Optoelectronics (NASDAQ:AAOI) stock is leading it as buying spreads across the companies building high-speed connections for artificial intelligence data centers. Applied Optoelectronics stock is at $115.49, up 8% in morning trading, well ahead of the larger optics names.

Meanwhile, Lumentum (NASDAQ:LITE | LITE Price Prediction) stock is climbing 3%, riding the same demand for faster optical connections. Coherent (NYSE:COHR) shares are rising 4%, which brings a second large optics supplier into the advance.

For a sector-wide gauge, the Roundhill Photonics & Optics ETF (CBOE:LYTE) is at $25.87, up 2%, a sign that the gains reach across a basket of optics stocks. The broader chip complex is firm as well, with the iShares Semiconductor ETF (NASDAQ:SOXX) at $591.17, up 3%, giving the optics rally a supportive background.

Optics Group Rallies Alongside Applied Optoelectronics No company announcement from Applied Optoelectronics comes with today’s move, which is running alongside gains across the optics and photonics group, turning a single-name jump into a sector story. The data-center expansion driving these optics names is the same thesis behind our report covering seven AI infrastructure suppliers that aren’t chipmakers, here.

Demand for faster connections explains why Applied Optoelectronics trades in step with its optics group. Applied Optoelectronics designs and manufactures optical transceivers and related components. These are used to move data inside and between data centers, and the company’s Q2 2026 revenue rose 86.4% year over year to $191.92 million as 800G product volumes more than doubled from the prior quarter. The company’s guidance calls for Q3 2026 revenue of $255 million to $290 million.

Applied Optoelectronics Outruns Lumentum and Coherent Lumentum stock is up 193% so far this year, and Coherent shares have gained 81% over the same stretch. Applied Optoelectronics stock has outrun both with a 231% advance since January, the largest climb in the group. The iShares Semiconductor ETF is up 97% over the same period, leaving the chip benchmark well behind the Applied Optoelectronics gain.

Scale separates Applied Optoelectronics from Lumentum and Coherent, which helps explain the sharper swings in Applied Optoelectronics stock. Revenue at Lumentum reached $1.01 billion in its Q4 FY2026, while Coherent posted $2.05 billion in revenue for its own Q4 FY2026. Michael Hurlston, Lumentum’s chief executive when the company reported on August 11, stated that “data center architects are turning to optical links as a primary means of connectivity.”

That demand supports the bullish outlook for Applied Optoelectronics. Thompson Lin, the company’s chief executive at the time of the August 6 earnings call, stated that “forecast demand continues to outpace our production capacity through mid-2027.” Options traders lean the same way, with the put-to-call ratio across the full options chain for Applied Optoelectronics stock at 0.24, a reading that shows bullish call contracts far outnumbering bearish puts.

However, Applied Optoelectronics still carries real risk. The company lost $22.78 million in Q2 under standard accounting, and its gross margin narrowed to 27.7% from 30.3% a year earlier. Customer concentration adds pressure, since the top 10 customers at Applied Optoelectronics made up 99% of the company’s Q2 revenue.

What the Applied Optoelectronics Rally Means for Investors Gains across the group confirm the Applied Optoelectronics move, making position sizing the central decision, and traders can watch the company’s Q3 results to see whether it delivers on its revenue guidance.

Production remains the swing factor for Applied Optoelectronics, since the company’s management has tied its near-term revenue almost entirely to factory capacity and component supply. Shareholders may want to keep an eye on whether the company’s additional Pearland and Houston facilities come online in early 2027 as planned.

Applied Optoelectronics stock carries a beta of 3.78, a gauge showing that it has historically moved far more sharply than the overall market. A moderate stake may balance its upside against that volatility, customer concentration and the risk that capacity expansion slips off schedule.

Contact [email protected] for any questions or corrections.